STAT+: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease

How 1 sources are covering this

• STATCenter·18h ago

  STAT+: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease

  A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost for sales.

  Read at STAT →